uniQure (QURE) Non-Current Deferred Tax Liability (2021 - 2026)
uniQure (QURE) posted quarterly Non-Current Deferred Tax Liability of $7.7 million for Q2 2026, down 2.98% year-over-year from $8.0 million in Q2 2025, and down 0.9% quarter-over-quarter from $7.8 million in Q1 2026.
uniQure (QURE) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
uniQure's Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $7.7 million for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability fell 2.98% year-over-year to $7.7 million; the TTM figure through Jun 2026 stood at $7.7 million (down 2.98% YoY), while the FY2025 annual figure was $8.0 million, up 13.12% from the prior year.
- Non-Current Deferred Tax Liability for Q2 2026 stood at $7.7 million, down from $7.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $11.3 million in Q1 2022, with the low at $4.9 million in Q3 2023.
- The 5-year median for Non-Current Deferred Tax Liability is $7.7 million (2024), against an average of $7.8 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability sank 42.77% in 2023, then soared 55.11% in 2024.
- uniQure's Non-Current Deferred Tax Liability stood at $8.3 million in 2022, then decreased by 8.65% to $7.5 million in 2023, then retreated by 6.63% to $7.0 million in 2024, then advanced by 13.12% to $8.0 million in 2025, then fell by 3.02% to $7.7 million in 2026.
- Business Quant data shows QURE's Non-Current Deferred Tax Liability at $7.7 million in Q2 2026, $7.8 million in Q1 2026, and $8.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | uniQure | 3.37 Bn | 3.37 Bn | 5.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.73 Mn |
| Jun 30, 2026 | 7.73 Mn |
| Mar 31, 2026 | 7.80 Mn |
| Mar 31, 2026 | 7.80 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Mar 31, 2025 | 7.34 Mn |
| Mar 31, 2025 | 7.34 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Sep 30, 2024 | 7.63 Mn |
| Sep 30, 2024 | 7.63 Mn |
| Jun 30, 2024 | 7.32 Mn |
| Jun 30, 2024 | 7.32 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Mar 31, 2024 | 7.38 Mn |